Mary Caffrey, Executive Editor of The American Journal of Managed Care, shared a post on LinkedIn:
“This year’s ASCO is full of news about making bold steps where the need is great: Dr. Hans Lee of Sarah Cannon Research Institute shared the first glimpses of what could be a breakthrough for patients with AL amyloidosis, and it involves a drug that’s already here: Regeneron’s linvoseltamab.”
Title: Lee Shares Early Data on Linvoseltamab in R/R AL Amyloidosis, Calls Responses “Unprecedented”
Author: Mary Caffrey
Other articles featuring Mary on OncoDaily.